Business Expansion into Vaccine Production and Development

Prestige Biopharma (PBP) has been preparing for a business expansion into the development of vaccine-based therapeutics since the start of the ongoing COVID-19 outbreak as a response to the current, and potential future, viral pandemics. The design, development and implementation of the vaccine centre has resulted from that plan.

PBP is on target to complete the construction of its global-scale vaccine production facility in Osong, South Korea with a total area of approximately 8,500 (meter square) inside the Campus 2 facility of its affiliated company Prestige Biologics. With a total production capacity of 100,000 liters, PBP vaccine centre is on target to meet surging global demands for COVID 19 vaccine.

The vaccine centre initiated construction in March 2021 and is projected to start test operations from August 2021. The  full production using 2,000 litre bioreactors will be processed from September.


Antibody-drug production know-how
- High similarity of Adenovirus-based vaccines & antibody-drug production process
- Large amount of single-use bioreactor bags
Prestige Biologics’ ALITA Smart BioFactory
- The world’s first smart factory system in bio-manufacturing designed based on digital AI (Artificial Intelligence)
- Fast and convenient change-over when catering for multiple products and manufacturing processes
Mass production using Single-Use system
- Smart BioFactory’s Single-Use system enables mass production of vaccine in the short-term
- Reduced risk of cross contamination and increase in operational efficiency
Reliable raw material supply chain
- Strategic partnership with Cytiva, top global bioprocessing equipment & solutions provider
Global scale vaccine manufacturing center

Pilot Vaccine Unit (PVU)


Location: 3F of Prestige Biologics Campus I

Manufacturing Capacity:

  • 400L of Capacity: 2 x 200L

Frontier Vaccine Unit (FVU)

Location: B1 of Prestige Biologics Campus I Annex

Manufacturing Capacity:

  • 2 modules consisting of 4 x 2,000L
  • 16,000L of capacity: 8 x 2,000L

Main Vaccine Unit (MVU)

Manufacturing Capacity:

  • 11 modules consisting of 4 x 2,000L
  • 88,000L of capacity: 44 x 2,000L

Location:

  • Prestige Biologics Campus II
  • Dedicated building of 8,500 (meter square)
  • 3 stories with manufacturing modules on the 2nd floor
Highlights

  • Full Single-Use System

– Smart BioFactory’s Single-Use system enables mass production of vaccine in the short-term

– Reduced risk of cross contamination and increase in operational efficiency

  • CEO (Customized Engineering Platform)

– The world’s first smart factory system in bio-manufacturing designed based on digital AI

– Fast and convenient change-over when catering for multiple products and manufacturing processes

  • Digitally Enabled Lab & IoT Controller

– Automated artificial intelligence / machine-learning-enabled process parameter control

– Real-time trending with the data from Smart Bio-Factory to Digitally Enabled Lab